International Biotechnology Trust’s Sarepta Therapeutics SRPT Stock Holding History

International Biotechnology Trust’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$3.23M	Buy	26,700 +7,900	+42%	+$893K	1.09%	27
2023 Q2	$2.15M	Buy	+18,800	New	+$2.42M	0.66%	36
2021 Q3	–	Sell	-31,500	Closed	-$2.45M	–	74
2021 Q2	$2.45M	Hold	31,500	–	–	0.65%	35
2021 Q1	$2.35M	Hold	31,500	–	–	0.62%	30
2020 Q4	$5.36M	Hold	31,500	–	–	1.47%	20
2020 Q3	$4.42M	Buy	31,500 +10,000	+47%	+$1.52M	1.43%	22
2020 Q2	$3.5M	Sell	21,500 -6,600	-23%	-$898K	1.16%	22
2020 Q1	$2.74M	Sell	28,100 -12,000	-30%	-$1.37M	1.25%	19
2019 Q4	$5.17M	Buy	40,100 +14,000	+54%	+$1.41M	1.86%	19
2019 Q3	$1.97M	Hold	26,100	–	–	0.91%	26
2019 Q2	$3.96M	Buy	26,100 +12,300	+89%	+$1.49M	1.47%	22
2019 Q1	$1.64M	Sell	13,800 -3,200	-19%	-$411K	0.61%	42
2018 Q4	$1.46M	Sell	17,000 -10,000	-37%	-$1.25M	0.9%	28
2018 Q3	$3.34M	Hold	27,000	–	–	1.59%	24
2018 Q2	$3.57M	Hold	27,000	–	–	1.37%	25
2018 Q1	$2M	Hold	27,000	–	–	0.78%	31
2017 Q4	$1.5M	Sell	27,000 -94,000	-78%	-$4.98M	0.53%	43
2017 Q3	$5.49M	Buy	121,000 +60,000	+98%	+$2.4M	2.14%	15
2017 Q2	$2.06M	Buy	+61,000	New	+$1.99M	0.78%	38
2017 Q1	–	Sell	-21,000	Closed	-$576K	–	63
2016 Q4	$576K	Buy	+21,000	New	+$843K	0.26%	43

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

International Biotechnology Trust's SRPT Position: Q3 2023 in Review

International Biotechnology Trust increased its Sarepta Therapeutics (SRPT) stake by 42% in Q3 2023, buying an estimated $893K and bringing the position to 26,700 shares worth $3.23M. The position accounts for 1.09% of the portfolio, ranked #27.

International Biotechnology Trust first reported a position in SRPT in Q4 2016 and has held it in 20 quarters since. The position peaked at $5.49M in Q3 2017. 395 funds tracked by Wall St. Rank hold SRPT as of Q3 2023.

International Biotechnology Trust held 26,700 shares of Sarepta Therapeutics worth $3.23M as of Q3 2023.
International Biotechnology Trust bought 7,900 Sarepta Therapeutics shares in Q3 2023, an estimated $893K.
Sarepta Therapeutics made up 1.09% of International Biotechnology Trust's portfolio in Q3 2023, its #27 holding.
International Biotechnology Trust first reported a position in Sarepta Therapeutics in Q4 2016 and has held it in 20 quarters since.
International Biotechnology Trust's Sarepta Therapeutics position peaked at $5.49M in Q3 2017.
395 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2023.

Based on International Biotechnology Trust's 13F filing for Q3 2023, filed 14 Nov 2023.